(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(0.08%) $78.54
(0.82%) $2.21
(-0.36%) $2 322.70
(-0.37%) $27.51
(2.50%) $989.05
(0.18%) $0.930
(0.76%) $10.91
(0.44%) $0.799
(-0.05%) $91.30
1.34% € 34.15
Live Chart Being Loaded With Signals
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts...
Stats | |
---|---|
Volumen de hoy | 15 809.00 |
Volumen promedio | 22 056.00 |
Capitalización de mercado | 1.84B |
EPS | €0 ( 2024-03-27 ) |
Próxima fecha de ganancias | ( €0 ) 2024-05-15 |
Last Dividend | €1.050 ( 2023-06-15 ) |
Next Dividend | €0 ( N/A ) |
P/E | 29.44 |
ATR14 | €0.100 (0.29%) |
Volumen Correlación
Dermapharm Holding SE Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dermapharm Holding SE Correlación - Moneda/Commodity
Dermapharm Holding SE Finanzas
Annual | 2023 |
Ingresos: | €1.14B |
Beneficio Bruto: | €342.86M (30.20 %) |
EPS: | €1.160 |
FY | 2023 |
Ingresos: | €1.14B |
Beneficio Bruto: | €342.86M (30.20 %) |
EPS: | €1.160 |
FY | 2022 |
Ingresos: | €1.02B |
Beneficio Bruto: | €660.83M (64.49 %) |
EPS: | €2.49 |
FY | 2021 |
Ingresos: | €942.91M |
Beneficio Bruto: | €620.69M (65.83 %) |
EPS: | €3.89 |
Financial Reports:
No articles found.
Dermapharm Holding SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€1.050 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.770 | 2019-06-05 |
Last Dividend | €1.050 | 2023-06-15 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | €5.67 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.92 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.99 | |
Div. Directional Score | 7.91 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GRM.DE | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
RNT.F | Ex Dividend Junior | 2023-09-13 | Annually | 0 | 0.00% | |
BIRG.DE | Ex Dividend Junior | 2023-05-11 | Sporadic | 0 | 0.00% | |
ITU.DE | Ex Dividend Knight | 2023-10-06 | Quarterly | 0 | 0.00% | |
TNE5.DE | Ex Dividend Junior | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
CSH.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
MBB.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
WIB.DE | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
ENI.DE | Ex Dividend Knight | 2023-11-20 | Semi-Annually | 0 | 0.00% | |
OPC.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0549 | 1.500 | 8.90 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0286 | 1.200 | 9.05 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.114 | 1.500 | 9.84 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.598 | 0.800 | 7.01 | 5.61 | [1 - 3] |
quickRatioTTM | 0.760 | 0.800 | -0.238 | -0.191 | [0.8 - 2.5] |
cashRatioTTM | 0.402 | 1.500 | 8.88 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.489 | -1.500 | 1.855 | -2.78 | [0 - 0.6] |
interestCoverageTTM | 3.07 | 1.000 | 9.98 | 9.98 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.01 | 2.00 | 8.66 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.24 | 2.00 | 8.38 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.979 | -1.500 | 2.08 | -3.13 | [0 - 2.5] |
grossProfitMarginTTM | 0.543 | 1.000 | 4.28 | 4.28 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.156 | 1.000 | 8.88 | 8.88 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.203 | 1.000 | 9.99 | 9.99 | [0.2 - 2] |
assetTurnoverTTM | 0.520 | 0.800 | 9.87 | 7.89 | [0.5 - 2] |
Total Score | 10.83 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 29.09 | 1.000 | 7.16 | 0 | [1 - 100] |
returnOnEquityTTM | 0.114 | 2.50 | 9.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.24 | 2.00 | 8.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.01 | 2.00 | 8.66 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.190 | 1.000 | 7.74 | 0 | [0.1 - 0.5] |
Total Score | 4.99 |
Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico